Generic Name:
fremanezumab
Project Status:
Complete
Therapeutic Area:
migraine
Manufacturer:
Teva Canada Innovation
Call for patient/clinician input open:
Brand Name:
Ajovy
Project Line:
Reimbursement Review
Project Number:
SR0641-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the prevention of migraine in adults who have at least 4 migraine days per month.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.